Kempegowda Institute of Medical Sciences (KIMS),
Bangalore-560070 Department of Community Medicine
List of sponsored projects
|
Sl.No |
Title of the Project |
Year |
Principal Investigator | Sponsors |
|
1 |
An evaluation of vaccination coverage of children in rural community |
1985 |
Dr. M. K. Sudarshan | Karnataka state council for science and technology (KSCST) |
|
2 |
Coverage evaluation survey of immunization programme in Bangalore urban district |
1989 |
Dr. M. K. Sudarshan | UNICEF, Hyderabad |
|
3 |
Epidemiological survey of water borne diseases in the Karnataka region of Kaveri basin |
1990 |
Dr. M. K. Sudarshan | Ministry of Environment & Forests, Govt. of India / Bangalore University |
|
4 |
An epidemiological study of rabies in Bangalore city |
1992 |
Dr. M. K. Sudarshan | Karnataka state council for science and technology (KSCST) |
|
5 |
An evaluation of cold chain system for vaccines in the city of Bangalore |
1992 |
Dr. M. K. Sudarshan | Karnataka state council for science and technology (KSCST) |
|
6 |
An estimation of manpower and material requirement for a new primary health center- K. Gollahally, Bangalore urban district, Karnataka state, India |
1993 |
Dr. M. K. Sudarshan | WHO-SEARO/ NIHFW, New Delhi |
|
7 |
A sero-epidemiological survey of HIV among jail inmates in Bangalore |
1994 |
Dr. M. Sundar | Karnataka state council for science and technology (KSCST) |
|
8 |
Clinical evaluation of safety & immunogenicity of PCEC rabies vaccine (Kaketsuken) in post-exposure treatment |
1994 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune. |
|
9 |
Multi indicator coverage evaluation survey (MIS) of Chitradurga district, Karnataka |
1996 |
Dr. M. Sundar | Govt. of Karnataka / UNICEF, Hyderabad |
|
10 |
Multi-indicator coverage evaluation survey (MIS) of Bangalore rural district |
1996 |
Dr. M. S. Rajanna | Govt. of Karnataka / UNICEF, Hyderabad |
|
11 |
Clinical evaluation of safety and efficacy of PVRV (Verorab) in post exposure treatment during pregnancy |
1996 |
Dr. M. K. Sudarshan | Pasteur Merieux Connaught,France |
|
12 |
Clinical evaluation of safety and immunogenicity of inactivated Hepatitis ‘A’ vaccine (Avaxim) in adults – Phase-III clinical trial |
1997 |
Dr. M. K. Sudarshan | Pasteur Merieux Connaught, France |
|
13 |
Evaluation of pulse polio immunization and routine immunization in Karnataka state |
1998 |
Dr. M. S. Rajanna | UNICEF, Hyderabad |
|
14 |
Evaluation on safety and efficacy of Albendazole in intestinal helminthiasis |
1998 |
Dr. M. K. Sudarshan | Juggat Pharma, Bangalore |
|
15 |
Evaluation of baby friendly hospitals in Karnataka |
1998 |
Dr. M. K. Sudarshan | Breastfeeding promotion network of India (BPNI) /UNICEF |
|
16 |
Clinical evaluation of safety and immunogenicity of Rhesus Diploid Rabies Vaccine (RDRV) in man |
1999 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune. |
|
17 |
Screening of neonates and children for blood lead levels in KIMS- Project Lead free |
1999 |
Dr. M. K. Sudarshan | George Foundation, USA |
|
18 |
Comparative evaluation of tolerance and acceptability of DTaP vaccine with DTwP and DT as second booster at five years |
2000 |
Dr. M. K. Sudarshan | Aventis Pasteur, France |
|
19 |
A phase III open, comparative clinical trial to assess the safety and immunogenicity of Human Diploid Cell Vaccine (HDCV)(Adsorbed) manufactured by SII, Pune with standard commercially available HDCV rabies vaccine |
2001 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune. |
|
20 |
National multi-centric study on monitoring of quality of iodized salt to prevent IDD and increase production of iodized salt through networking of medical colleges in South India ( two districts of Karnataka) |
2001 |
Dr.D. H. Ashwath Narayana | Government of India |
|
21 |
Improvisation of management information system (MIS) ofIndia population project VIII- urban health centers in Bangalore city |
2001 |
Dr. M. K. Sudarshan | World Bank/BMP |
|
22 |
A phase III open, comparative clinical trial to assess the safety and immunogenicity of Human Diploid Cell Vaccine (HDCV) (Lyophilized- Pittman Moore strain) manufactured by SII, Pune with standard commercially available HDCV (Lyophilized) of Aventis Pasteur in post exposure treatment |
2002 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune. |
|
23 |
Morbidity and mortality survey and health seeking behavior in urban and rural field practice area of KIMS |
2003 |
Dr.D.H. Ashwath Narayana | NIHFW, New Delhi |
|
24 |
Validation of early diagnosis and prevention system software (EDPS) using computers at PHC, Kengeri |
2003 |
Dr. M. K. Sudarshan | John Hopkins & George Foundation, USA. |
|
25 |
A phase IV, open label, comparative clinical trial to assess the efficacy of Human Diploid Cell Rabies Vaccine (Adsorbed) with that of standard commercially available Human Diploid cell Rabies Vaccine (Lyophilized) in post exposure Rabies treatment |
2004 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune |
|
26 |
A phase IV, open label, comparative clinical trial to assess the efficacy of Human Diploid Cell Rabies Vaccine (Lyophilized) with that of standard commercially available Human Diploid cell Rabies Vaccine (Lyophilized) in post exposure rabies treatment |
2004 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune |
|
27 |
A phase IV, post marketing surveillance study to assess the immunogenicity and reactogenicity of Human Diploid cell Rabies vaccine (Adsorbed, Rabivax ) manufactured by Serum Institute of India. |
2004 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune |
|
28 |
An open label, phase IV, comparative clinical trial to assess the safety and efficacy of Human Diploid Cell rabies Vaccine (liquid) (Rabivax) with Purified Chick Embryo Cell (PCEC) rabies vaccine (Rabipur) |
2004 |
Dr. M. K. Sudarshan | Serum Institute of India, Pune. |
|
29 |
Assessing burden of rabies in India- A national multicentric rabies survey |
2004 |
Dr. M. K. Sudarshan | WHO-APCRI |
|
30 |
A multicenter study to assess the safety & immunogenicity of Vaxirab in post-exposure cases |
2005 |
Dr. B. J. Mahendra | Cadila Healthcare Ltd., Ahmedabad |
|
31 |
A multicenter study to assess the Safety and Immunogenicity of Vaxirab Vs Lyssavac N Berna in simulated post-exposure prophylaxis |
2005 |
Dr. B. J. Mahendra | Cadila Healthcare Ltd. Ahmedabad |
|
32 |
A phase IV, single center, randomized, open-label, parallel group immunogenicity and reactogenicity study in healthy volunteers, comparing PCECV(Rabipur) administered intradermally at two sites in a dose of 0.1ml per site or PCECV dministered intramuscularly at a dose of 1.0ml, both on 0,3,7,14,28 (Essen post-exposure scheme) |
2005 |
Dr. M. K. Sudarshan | Chiron vaccines, Germany |
|
33 |
A multi center, phase III, randomized, double blind comparative study to evaluate the safety & immunogenicity of rabies vaccine (Indirab) in animal bite cases- anequivalence trial |
2007 |
Dr. B. J. Mahendra | Bharat Biotech International Ltd, Hyderabad |
|
34 |
A performance audit of animal birth control (ABC) programme in Bangalore city |
2007 |
Dr. M. K. Sudarshan | Bruhat Bangalore Mahanagara palike |
|
35 |
Prevalence of food allergy in urban & rural of Bangalore – An Euro Prevall study. |
2007 |
Dr. B. G. Parasuramalu | Institute of food research (IFR), United Kingdom |
|
36 |
Clinical evaluation of safety & immunogenicity of purified chick embryo cell rabies vaccine administered intradermally using updated TRC regimen (2-2-2-0-2) in animal bite cases. |
2007 |
Dr.D. H. Ashwath Narayana | Novartis Vaccines, Mumbai, India |
|
37 |
Assessing the burden of bronchial asthma in rural adult population |
2008 |
Dr. B. G. Parasuramalu | RGUHS, Bangalore |
|
38 |
Clinical evaluation of safety & immunogenicity of Indirab & Verorab vaccines using updated Thai Red Cross regimen in healthy volunteers: Phase III, randomized clinical study |
2008 |
Dr.D. H. Ashwath Narayana | Bharat Biotech International Ltd, Hyderabad |
|
39 |
A comparative multi centre study to assess the immunogenicity and safety of PDEV (Vaxirab) versus PCEC Vaccine (Rabipur) and PVRV (Verorab) in post exposure cases |
2008 |
Dr.D. H. Ashwath Narayana | Cadila Health Care, Ahmedabad |
|
40 |
An open label study to assess the safety &immunogenicity of PCECPM vaccine administred intramuscularly using pre exposure vaccination in healthy volunteers. |
2009 |
Dr.D. H. Ashwath Narayana | Cadila Healthcare Ltd. Ahmedabad |
|
41 |
An open label study to assess safety & immunogenicity of PCECPM vaccine administred intramuscularly using simulated post exposure prophylaxis |
2009 |
Dr.D. H. Ashwath Narayana | Cadila Healthcare Ltd. Ahmedabad |
|
42 |
Adopt a Village – A rural rabies prevention project |
2009 |
Dr M K Sudarshan- Advisor Dr.D. H. Ashwath Narayana– Project Coordinator Dr.N. R. Ramesh Masthi – Project officer (Medical) | Global alliance for rabies control (GARC), USA; Rabies in Asia (RIA)Foundation &Commonwealth Veterinary Association (CVA) |
|
43 |
An open label, multicentric study to assess safety & immunogenicity of PCECPM vaccine administred intramuscularly using PEP in animal bite cases |
2010 |
Dr.D. H. Ashwath Narayana | Cadila Healthcare, Ahmedabad |
|
44 |
Clinical evaluation of safety & immunogenicity of PCECPM vaccine administred intradermally using updated TRC regimen in healthy volunteers |
2010 |
Dr.D. H. Ashwath Narayana | Cadila Healthcare, Ahmedabad |
|
45 |
Comparative study to assess the safety & immunogenicity of PCECV & PVRV rabies vaccines administred intradermally using new one week regimen (4-4-4-0-0) in healthy volunteers |
2010 |
Dr.D. H. Ashwath Narayana | Rabies in Asia- India Chapter |
|
46 |
Safety and immunogenicity study for use of Meningococcal (Groups A,C,Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra) in healthy subjects 2-55 years of age in India. |
2010 |
Dr.M. K. Sudarshan & Dr.D. H. Ashwath Narayana | Sanofi Pasteur, France |
|
47 |
What’s on my hands study |
2010 |
Dr.Jayanthi Srikanth | Indian Public Health Association & HUL (Life buoy division) |
|
48 |
A phase IV, multi-center, randomized, open-label study of PCECV (Rabipur®) comparing the immunogenicity and safety of two different simulated post exposure schedules (Zagreb 2-1-1 vs Essen regimen 1-1- 1-1-1) in Healthy Indian subjects |
2011 |
Dr.D. H. Ashwath Narayana | Novartis vaccines |
|
49 |
Comparative study on safety & Immunogenicity of Vaxirab-N vs
Rabipur |
2012 |
Dr. H. S. Ravish | Cadila Health care Pvt. Ltd. |
|
50 |
Situational analysis of health professionals education in India |
2012 |
Dr. D. H Ashwath Narayana | Public Health Foundation of India, New Delhi |
|
51 |
Prospective dengue seroprevalence study in 5 to 10 year old children in India |
2012 |
Dr. N. R. Ramesh Masthi | Sanofi Pasteur |
|
52 |
A Phase II/III randomized, multi-centric, comparator-controlled study of the safety and neutralizing activity of a human monoclonal antibody to rabies (SII RMAb) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure. |
2013 |
Dr. D. H Ashwath Narayana | Serum Institute of India, Pune |
|
53 |
Assessing safety and immunogenicity of PCECV (Rabipur) and PVRV (Verorab) administered using one week intra dermal regimen (4-4-4) in animal bite cases. |
2013 |
Dr. D. H Ashwath Narayana | Rabies in Asia Foundation |
|
54 |
Occupational Asthma in silk workers |
2014 |
Dr. Giriyanna Gowda | Medical Education & Research Trust, Bangalore |
|
55 |
Immunogenicity and safety of rabies G protein vaccine administered as simulated post-exposure immunization in healthy volunteers |
2016 |
Dr. H. S. Ravish | Cadila Pharmaceutical Ltd, Ahmedabad |
|
56 |
Respiratory morbidities among school children post Diwali in Bangalore city |
2018 |
Dr. Giryanna Gowda | Medical Education & Research Trust, Bangalore |
|
57 |
Assembling new evidence in support of elimination of dog mediated human rabies from India – Indian multicentric rabies study – 2017 -2018 |
2018 |
Dr . Ashwath Narayana Dr.Ramesh Masthi N.R. |
World Health Organisation , D.H Geneva and APCRI |
|
58 |
A phase 2/3 randomized observer blind , controlled multicentre study to evaluate the lot to lot consistency of SIIPL Meningococcal ACYWX conjugate vaccine (Nm CV-5) and to compare its safety and immunogenicity with that of licensed Meningococcal ACWY menactra in healthy individuals 18-85yrs of age |
2019-20 |
Dr. Ravish H.S. | Serum Institute of India, Pune |
|
59 |
A phase IV, randomized controlled study of the safety and immunogenicity of Rabishield + Rabivax – S post exposure prophylaxis regimen in patients with potential rabies exposure |
2019 |
Dr. Ravish H.S. | Serum Institute of India, Pune |
